FdaApplication
ANDA 203844
Identifiers
- fda_app_no: ANDA203844
Properties
| Property | Value |
|---|---|
| applicant_name | CADILA PHARMACEUTICALS LTD |
| application_type | ANDA |
| approval_date | 2017-02-13 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RIVASTIGMINE TARTRATE | RIVASTIGMINE TARTRATE | EQ 3MG BASE | CAPSULE;ORAL |
| RIVASTIGMINE TARTRATE | RIVASTIGMINE TARTRATE | EQ 4.5MG BASE | CAPSULE;ORAL |
| RIVASTIGMINE TARTRATE | RIVASTIGMINE TARTRATE | EQ 1.5MG BASE | CAPSULE;ORAL |
| RIVASTIGMINE TARTRATE | RIVASTIGMINE TARTRATE | EQ 6MG BASE | CAPSULE;ORAL |
4 products